FDA warns diagnostic maker for failing to seek approval for changes, OTC firm for lax investigations

The US Food and Drug Administration (FDA) recently sent warning letters to a subsidiary of device manufacturer Abbott and to an over-the-counter (OTC) drugmaker following inspections in 2022.